Bristol-Myers Squibb 配当と自社株買い

配当金基準チェック /46

Bristol-Myers Squibb配当を支払う会社であり、現在の利回りは4.1%です。

主要情報

4.1%

配当利回り

バイバック利回り

総株主利回り	4.1%
将来の配当利回り	4.3%
配当成長	5.5%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	US$2.400
配当性向	-67%

最近の配当と自社株買いの更新

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 21

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 07

Recent updates

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Aug 15

Bristol-Myers Squibb: A Potential Comeback In Healthcare

Aug 06

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Jul 27

Bristol Myers Squibb: The More It Drops, The More I Buy

Jul 16

Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?

Jun 13

Bristol Myers: Quality Fundamentals Suppressed By Interest Rates

Jun 09

Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss

Jun 03

Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

May 23

Bristol-Myers Squibb: A Lost Decade?

May 03

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

Apr 29

Is Bristol Myers Squibb A Buy At These Bottom Levels?

Apr 22

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

Apr 12

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

Apr 02

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 21

Bristol-Myers Squibb Is Not A Buy For Me

Mar 19

Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield

Mar 07

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 07

決済の安定と成長

配当データの取得

安定した配当: BMYの1株当たり配当金は過去10年間安定しています。

増加する配当: BMYの配当金は過去10年間にわたって増加しています。

配当利回り対市場

Bristol-Myers Squibb 配当利回り対市場

BMY 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (BMY)	4.1%
市場下位25% (US)	1.4%
市場トップ25% (US)	4.4%
業界平均 (Pharmaceuticals)	2.4%
アナリスト予想 (BMY) (最長3年)	4.3%

注目すべき配当: BMYの配当金 ( 4.1% ) はUS市場の配当金支払者の下位 25% ( 1.38% ) よりも高くなっています。

高配当: BMYの配当金 ( 4.1% ) はUS市場の配当金支払者の上位 25% ( 4.35% ) と比較すると低いです。

株主への利益配当

収益カバレッジ: BMYは配当金を支払っていますが、会社は利益を上げていません。

株主配当金

キャッシュフローカバレッジ: BMYの現金配当性向 ( 35.3% ) は比較的低く、配当金の支払いはキャッシュフローによって十分にカバーされています。

Bristol-Myers Squibb 配当と自社株買い

配当金 基準チェック /46

主要情報

最近の配当と自社株買いの更新

Upcoming dividend of US$0.60 per share

Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024

Upcoming dividend of US$0.60 per share

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Recent updates

Price target increased by 7.4% to US$58.64

Bristol-Myers Squibb Company Showcases the Continued Strength of Its Cardiovascular Portfolio with New Clinical and Real-World Data At American Heart Association Scientific Sessions 2024

Bristol Myers Squibb Presents New Long-Term Data from the EMERGENT Program Evaluating Covenfy in Adults with Schizophrenia At Psych Congress 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data At Psych Congress 2024

Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren

Bristol-Myers Squibb: A High-Yield Bargain With Growth On The Horizon

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-To-Severe Scalp Psoriasis and in A Real-World Setting

Upcoming dividend of US$0.60 per share

Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)

U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY (xanomeline and Trospium Chlorx), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Bristol Myers Squibb Announces New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from Checkmate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® Plus Yervoy® in Advanced Melanoma

Second quarter dividend of US$0.60 announced

Bristol-Myers Squibb Company to Report Q3, 2024 Results on Oct 31, 2024

Bristol-Myers Still A Value Play Despite Appreciating 26.56% From 2024 Lows

Bristol Myers Squibb Announces Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS (Mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Bristol-Myers Squibb: A Potential Comeback In Healthcare

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Consensus EPS estimates fall by 18%

Bristol-Myers Squibb Company Announces Intangible Asset Impairment Charges for the Three Months Ended June 30, 2024

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb: The More It Drops, The More I Buy

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Bristol-Myers Squibb Company to Report Q2, 2024 Results on Jul 26, 2024

First quarter dividend of US$0.60 announced

Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024

Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024

Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?

Bristol Myers: Quality Fundamentals Suppressed By Interest Rates

Bristol Myers Squibb Announces Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial

Bristol Myers Squibb’S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting

Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine

Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

Bristol Myers Squibb Announces New Four-Year Results from the POETYK PSO Long-Term Extension Trial of Sotyktu (Deucravacitinib) Treatment in Adult Patients with Moderate-To-Severe Plaque Psoriasis

Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol-Myers Squibb: A Lost Decade?

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Bristol Myers Squibb A Buy At These Bottom Levels?

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

Consensus EPS estimates fall by 24%

Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept)

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease

Upcoming dividend of US$0.60 per share

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Bristol-Myers Squibb Company, Annual General Meeting, May 07, 2024

Bristol-Myers Squibb Is Not A Buy For Me

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Executive Chairman of the Board exercised options and sold US$3.6m worth of stock

Bristol-Myers Squibb Company to Report Q1, 2024 Results on Apr 25, 2024

U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo

配当金基準チェック /46